What is the 13F Pro Quality Score for ANRO?

13F Pro ranks Alto Neuroscience, Inc. (ANRO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANRO's current score at https://13fpro.ai/research/ANRO (free sign-up required for the full ranking).

Which hedge funds own the most ANRO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ANRO include Alpha Wave Global,, Commodore Capital, Vestal Point Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ANRO as soon as new 13F filings post.

Where does 13F Pro source ANRO data?

All Alto Neuroscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alto Neuroscience, Inc. files with the SEC under CIK 1999480. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANRO in?

Alto Neuroscience, Inc. (ANRO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANRO research updated on 13F Pro?

ANRO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alto Neuroscience, Inc.(ANRO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1999480 ANRO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ANRO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alto Neuroscience, Inc. (ANRO), a Healthcare sector company. ANRO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Alto Neuroscience, Inc. reports net income of $-26.2M, free cash flow of $-27.6M. Top institutional holders of ANRO by reported 13-F value include Alpha Wave Global,, Commodore Capital, Vestal Point Capital,, based on the most recent SEC filings. ANRO trades on the NYSE exchange and files with the SEC under CIK 1999480. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alto Neuroscience, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-26.2M

Free Cash Flow

Q1 2026

$-27.6M

D/E Ratio

Q1 2026

0.07

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-69.2% YoY

$-61.4MFY 2024

FY23 $-36.3MFY24 $-61.4M

Operating Income

-81.5% YoY

$-68.6MFY 2024

FY23 $-37.8MFY24 $-68.6M

EPS (Diluted)

-79.9% YoY

$-2.50FY 2024

FY23 $-1.39FY24 $-2.50

Total Assets

+104.9% YoY

$177.5MFY 2024

FY23 $86.6MFY24 $177.5M

Total Debt

+4.0% YoY

$10.3MFY 2024

FY23 $9.9MFY24 $10.3M

Op. Cash Flow

-41.8% YoY

$-47.4MFY 2024

FY23 $-33.4MFY24 $-47.4M

Metric	FY 2024	FY 2023
Net Income	$-61.4M -69.2%	$-36.3M
Operating Income	$-68.6M -81.5%	$-37.8M
EPS (Diluted)	$-2.50 -79.9%	$-1.39
Total Assets	$177.5M +104.9%	$86.6M
Total Debt	$10.3M +4.0%	$9.9M
Operating Cash Flow	$-47.4M -41.8%	$-33.4M

AI Insight: ANRO Financial Trends

Alto Neuroscience's cash burn accelerated sharply in Q1 2026, with operating cash flow deteriorating to -$27M while equity surged $92M quarter-over-quarter, signaling recent capital raise masking deepening operational losses.

• Operating cash outflow worsened to -$27M in Q1 2026 from -$10M in Q3 2025, the worst quarter in the two-year trend.

• Net loss expanded to -$26M in Q1 2026 versus -$14M in Q3 2025, reversing three quarters of sequential improvement.

• Total debt rose to $16M and equity jumped to $243M in Q1 2026, consistent with a substantial equity financing event.

⚠ Operating cash burn in Q1 2026 (-$27M) now exceeds quarterly net losses; runway sustainability depends on recent capital deployment.

⚠ Deterioration in operating margin and cash burn reverses 6-quarter trend of modest improvement; signals potential acceleration in cash consumption.

AI Insight: ANRO Ratio Trends

Alto Neuroscience remains unprofitable across all return metrics, with ROE, ROA, and ROIC all negative and volatile through Q1 2026.

• ROE deteriorated from -35.7% in Q2 2024 to -43.1% in Q1 2026, reflecting persistent losses and negative equity returns.

• ROIC worsened from -38.2% in Q2 2024 to -41.9% in Q1 2026, indicating capital deployment failure across the period.

• Debt-to-equity ratio increased from 0.07 in Q2 2024 to 0.07 in Q1 2026, with interim peak of 0.18 in Q3 2025.

⚠ Q2 2025 marked peak deterioration with ROE at -57.4% and ROA at -44.9%; recovery to -43.1% and -38.0% in Q1 2026 warrants monitoring.

⚠ Leverage spike to 0.18 D/E in Q3 2025 has receded to 0.07, but equity and asset returns remain deeply negative.

Get alerted when ANRO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alto Neuroscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANRO

Alpha Wave Global, LP
$83.4M3,707,757 sh
Commodore Capital LP
$61.2M2,723,196 sh
Vestal Point Capital, LP
$46.4M2,064,075 sh
PERCEPTIVE ADVISORS LLC
$45.2M2,009,893 sh
Spruce Street Capital LP
$29.1M1,325,210 sh
VANGUARD CAPITAL MANAGEMENT LLC
$27.1M1,207,025 sh
FRANKLIN RESOURCES INC
$24.8M1,101,874 sh
Vivo Capital, LLC
$23.3M1,035,551 sh
ARMISTICE CAPITAL, LLC
$20.5M912,000 sh
MILLENNIUM MANAGEMENT LLC
$18.5M821,982 sh

Fund	Value	Shares
Alpha Wave Global, LP	$83.4M	3,707,757
Commodore Capital LP	$61.2M	2,723,196
Vestal Point Capital, LP	$46.4M	2,064,075
PERCEPTIVE ADVISORS LLC	$45.2M	2,009,893
Spruce Street Capital LP	$29.1M	1,325,210
VANGUARD CAPITAL MANAGEMENT LLC	$27.1M	1,207,025
FRANKLIN RESOURCES INC	$24.8M	1,101,874
Vivo Capital, LLC	$23.3M	1,035,551
ARMISTICE CAPITAL, LLC	$20.5M	912,000
MILLENNIUM MANAGEMENT LLC	$18.5M	821,982

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANRO on your watchlist

Track score changes the day Alto Neuroscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANRO a good stock to buy?

13F Pro's AI-powered analysis of Alto Neuroscience, Inc. (ANRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANRO are available on the ANRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANRO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alto Neuroscience, Inc.'s investment landscape.